OTC •
Healthcare •
Biotechnology •
Quote as of 05/08/2026 11:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization423.47 mln
Float1,366 mln
Earnings Date04/08/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
72
/ 100
Outperforming
Debt / Equity
-0.26
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0.00%
No payout
Business Description
CytoDyn Inc. is a Washington-based medical research company focused on developing a drug called leronlimab, which works by blocking a specific protein receptor in the body. The company is currently running clinical trials to explore how this drug might help patients with certain cancers, including colorectal cancer and triple-negative breast cancer. Founded in 2002, CytoDyn works alongside partner organization Creatv Bio to advance its research goals.
